SERAXIS Inc. publishes clinical trial considerations for a type 1 diabetes stem cell-derived therapy |
| November 12, 2018 | November 2018 Bond Updates |
|
GERMANTOWN, Md., Nov. 12, 2018 /PRNewswire/ -- SERAXIS Inc., a rapidly growing regenerative medicine company today announced the publication of important trial considerations for SR-01, its pluripotent stem cell-derived islet therapy for insulin-dependent diabetes. An analysis of islet... |
| View more at: https://www.prnewswire.com:443/news-releases/seraxis-inc-publishes-clinical-trial-considerations-for-a-type-1-diabetes-stem-cell-derived-therapy-300747501.html |
| Related News |
|